Why the study?
Major advances across pulmonary hypertension subtypes cast new light on pathogenetic mechanisms, epidemiology, diagnostic approaches, and therapeutics, warranting a summary of key basic, translational, and clinical reports.
This contemporary review highlights recent advances in the diagnosis and management of pulmonary hypertension, including updated definitions and emerging therapies like sotatercept.
Updates PH literature synthesis; leaves open prospective validation of revised definitions and sotatercept integration.
Major advances in pulmonary arterial hypertension, pulmonary hypertension (PH) associated with lung disease, and chronic thromboembolic PH cast new light on the pathogenetic mechanisms, epidemiology, diagnostic approach, and therapeutic armamentarium for pulmonary vascular disease. Here, we summarize key basic, translational, and clinical PH reports, emphasizing findings that build on current state-of-the-art research. This review includes cutting-edge progress in translational pulmonary vascular biology, with a guide to the diagnosis of patients in clinical practice, incorporating recent PH definition revisions that continue emphasis on early detection of disease. PH management is reviewed including an overview of the evolving considerations for the approach to treatment of PH in patients with cardiopulmonary comorbidities, as well as a discussion of the groundbreaking sotatercept data for the treatment of pulmonary arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: